课题基金 / 基金详情

A novel mechanism of stromal cell-derived factor 1 protection against diabetic cardiomyopathy

A novel mechanism of stromal cell-derived factor 1 protection against diabetic cardiomyopathy
基质细胞衍生因子 1 预防糖尿病心肌病的新机制
批准号:
9883646
负责人:
Yi Tan
金额:
$38.38万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-05-01 至 2022-02-28

项目摘要

项目成果

Yi Tan的其他基金

相似基金

相关文献

中文摘要
翻译
糖尿病心肌病(DCM)是糖尿病患者的主要慢性并发症之一。传统型 治疗扩张型心肌病的治疗方法包括控制血糖、控制高血压、降脂和 生活方式的管理。然而,目前还没有专门针对 扩张型心肌病的发病机制。需要对扩张型心肌病的致病机制有更深入的了解 改进治疗策略。 基质细胞衍生因子-1(SDF-1)属于C-X-C基序趋化因子家族。它控制着不同的细胞 通过与其受体CXCR4和CXCR7相互作用而发挥作用。心肌SDF-1一过性上调 在缺血期间或脑梗塞后,可将干细胞吸引到损伤部位,从而促进心脏 再生和血管生成。外源性SDF-1有助于预防心肌梗死和 通过干细胞依赖和非依赖机制造成的缺血/再灌注损伤。然而,这个角色 SDF-1-CXCR4/CXCR7系统在DCM中的作用机制尚未建立。 越来越多的证据表明,糖尿病导致的SDF-1等生长因子缺乏是 与糖尿病心血管并发症有关。在一项初步研究中,PI显示 SDF-1在1型和2型糖尿病小鼠心脏组织中的表达显著下调, 而受体的表达水平不受影响。PI认为心脏SDF-1的缺乏可能 有助于DCM,补充SDF-1可能提供直接的心肌保护作用。作为初步测试 培养的心肌细胞暴露于SDF-1预处理的类似棕榈酸酯的糖尿病脂肪毒性。 这些研究表明,SDF-1通过CXCR7-保护棕榈酸酯诱导的细胞死亡,但不能 CXCR4-,介导AMP激活的蛋白激酶(AMPK)激活。研究结果具有重要意义。 因为他们证明SDF-1可以提供独立于糖尿病心脏细胞死亡的直接保护 干细胞。因此,确定体内保护是否涉及相同的直接作用至关重要。 在分离的心肌细胞上鉴定出SDF-1。基于CXCR4和CXCR7在 心血管疾病,假设SDF-1治疗糖尿病小鼠直接预防 CXCR7介导的AMPK激活介导的糖尿病心肌细胞死亡和心脏重构 而SDF-1治疗最终可以预防DCM。 这一假设将通过三个具体的目标来检验:(1)确定心肌细胞的直接影响 研究SDF-1对DCM的保护作用;(2)确定SDF-1信号是否通过CXCR7介导 对DCM的保护,独立于CXCR4;(3)确定AMPK是否介导SDF-1/CXCR7 针对DCM的保护。 该项目将为SDF-1-CXCR4和/或-CXCR7在 心肌细胞作为未来临床研究中预防DCM的新治疗靶点。
英文摘要
Diabetic cardiomyopathy (DCM) is one of the major chronic complications in diabetic patients. Conventional therapies for treatment of DCM include glycemic control, management of hypertension, lowering lipid and life-style management. However, there are no treatment strategies available that specifically target the pathogenesis of DCM. Greater understanding of the pathogenic mechanism of DCM is needed to develop improved therapeutic strategies. Stromal cell-derived factor-1 (SDF-1) belongs to C-X-C motif chemokine family. It controls diverse cell functions by interacting with its receptors, CXCR4 and CXCR7. Myocardial SDF-1 is transiently up-regulated during ischemia or after infarction and can attract stem cells to the injury site contributing to cardiac regeneration and angiogenesis. Exogenous SDF-1 can help prevent myocardial infarction and ischemia/reperfusion injury through stem cell-dependent and -independent mechanisms. However, the role and mechanism of the SDF-1-CXCR4/CXCR7 system in DCM has not been established. Accumulating evidence indicates that diabetes-induced deficiency of growth factors such as SDF-1 is associated with diabetic cardiovascular complications. In a preliminary study, the PI showed that the expression of SDF-1 is notably down-regulated in the cardiac tissue of mice with type 1 and type 2 diabetes, while the receptor expression levels are unaffected. The PI considered that lack of cardiac SDF-1 may contribute to DCM and supplementary SDF-1 may provide direct cardiomyocyte protection. As an initial test cultured cardiac cells were exposed to palmitate-mimicked diabetic lipotoxicity with SDF-1 pretreatment. These studies showed that SDF-1 protected against palmitate-induced cell death via CXCR7-, but not CXCR4-, mediated AMP-activated protein kinase (AMPK) activation. The results are of great significance since they demonstrate SDF-1 can provide direct protection against diabetic cardiac cell death independent of stem cells. Therefore, it is critical to determine if in vivo protection involves the same direct actions by SDF-1 identified on isolated cardiomyocytes. Based on the critical role of CXCR4 and CXCR7 in cardiovascular diseases, it is hypothesized that SDF-1 treatment of diabetic mice directly protects against diabetes-induced cardiomyocyte death and cardiac remodeling via CXCR7-mediated activation of AMPK and that SDF-1 treatment can ultimately prevent DCM. This hypothesis will be tested through three specific aims: (1) to determine the direct cardiomyocyte effects of SDF-1 in protection against DCM; (2) to determine whether SDF-1 signaling through CXCR7 mediates protection against DCM, independently of CXCR4; (3) to determine whether AMPK mediates SDF-1/CXCR7 protection against DCM. This project will provide fundamental evidence for the interaction of SDF-1-CXCR4 and/or -CXCR7 at the cardiomyocyte as a new therapeutic target for the prevention of DCM in future clinical investigations.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Fibroblast growth factor 1 prevents hyperlipidemia and atherosclerosis
  • 批准号:
    10345440
  • 项目类别:
  • 资助金额:
    $55.36万
  • 财政年份:
    2021
  • 负责人:
    Yi Tan
  • 依托单位:
Fibroblast growth factor 1 prevents hyperlipidemia and atherosclerosis
  • 批准号:
    10531887
  • 项目类别:
  • 资助金额:
    $54.56万
  • 财政年份:
    2021
  • 负责人:
    Yi Tan
  • 依托单位:
海外基金